Iladatuzumab vedotin
Product Specifications
UNSPSC Description
Iladatuzumab vedotin (DCDS-0780A) is an antibody–drug conjugate (ADC) containing humanized IgG1 anti-human CD79B monoclonal antibody (MCDS0593A; HY-P99656) conjugated to MMAE via a protease labile linker. Iladatuzumab vedotin uses novel THIOMAB technology (TDC) to consistently conjugate two MMAE molecules per antibody using engineered cysteine residues. Iladatuzumab vedotin has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research[1].
Target Antigen
Antibody-Drug Conjugates (ADCs)
Type
ADC Related
Related Pathways
Antibody-drug Conjugate/ADC Related
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/iladatuzumab-vedotin.html
Solubility
H2O
Smiles
[Iladatuzumab vedotin]
References & Citations
[1]Alex F Herrera, et al. Anti-CD79B Antibody-Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study. Clin Cancer Res. 2022 Apr 1;28(7):1294-1301.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99657/Iladatuzumab-vedotin-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99657/
Clinical Information
Phase 1
CAS Number
1906205-77-3
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items